FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 383 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe... November 20, 2019 Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and... June 12, 2023 New Research on Treating Hormone Receptor-Positive Breast Cancer From SABCS 2020 January 29, 2021 An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling... October 4, 2023 Load more HOT NEWS A Novel Model Helps Better Predict Risk of Cancer Development in... Final OS and the Exploratory Analysis of the Outcome with Osimertinib... FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer Study Shows CAR T-Cell Therapy Is Effective at Putting Childhood Leukemia...
